MET and non-small cell lung carcinoma: Notably, the incidence of MET amplification surges to nearly 20% in kidney papillary cell carcinomas (KIRP), a data point presented in Figure 3B. Moreover, MET amplification has been shown to confer resistance to therapies targeting the epidermal growth factor receptor (EGFR) in malignancies such as NSCLC and colorectal cancer, underlining its role in both cell survival and acquired resistance to EGFR-targeting therapies [56,58,59].